Kevzara Uniunea Europeană - română - EMA (European Medicines Agency)

kevzara

sanofi winthrop industrie - sarilumab - artrita, reumatoida - imunosupresoare - kevzara în asociere cu metotrexat (mtx) este indicat pentru tratamentul moderat la sever activă artrita reumatoida (ra) la pacienţii adulţi care au răspuns inadecvat la, sau care sunt intoleranta la unul sau mai multe boli modificarea anti-reumatice droguri (dmard). kevzara poate fi administrat ca monoterapie în caz de intoleranţă la mtx sau atunci când tratamentul cu mtx este inadecvat.

Dupixent Uniunea Europeană - română - EMA (European Medicines Agency)

dupixent

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenți pentru dermatită, cu excepția corticosteroizilor - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Bavencio Uniunea Europeană - română - EMA (European Medicines Agency)

bavencio

merck europe b.v. - avelumab - tumori neuroendocrine - alte medicamente antineoplazice, anticorpi monoclonali - bavencio este indicat ca monoterapie pentru tratamentul pacienților adulți cu carcinom cu celule merkel metastatic (mcc). bavencio în combinație cu axitinib este indicat pentru tratamentul de primă linie al pacienților adulți cu carcinom renal în stadiu avansat (ccr). bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc) who are progression-free following platinum‑based chemotherapy.

BAVENCIO 20 mg/ml România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

bavencio 20 mg/ml

merck serono s.p.a. - italia - avelumabum - conc. pt. sol. perf. - 20mg/ml - alte antineoplazice anticorpi monoclonali

DUPIXENT 200 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dupixent 200 mg

sanofi winthrop industrie - franta - dupilumabum - sol. inj. in seringa preumpluta - 175mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic

DUPIXENT 200 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dupixent 200 mg

sanofi-aventis deutschland gmbh - franta - dupilumabum - sol. inj. in stilou injector (pen) preumplut - 175mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic

DUPIXENT 300 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dupixent 300 mg

sanofi winthrop industrie - franta - dupilumabum - sol. inj. in seringa preumpluta - 150mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic

DUPIXENT 300 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dupixent 300 mg

sanofi winthrop industrie - franta - dupilumabum - sol. inj. in stilou injector (pen) preumplut - 150mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic

NIBIX 100 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

nibix 100 mg

terapia s.a. - imatinibum - caps. - 100mg - alte antineoplazice inhibitori de protein-kinaza

NIBIX 400 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

nibix 400 mg

terapia s.a. - imatinibum - caps. - 400mg - alte antineoplazice inhibitori de protein-kinaza